Anti-LOXL2 Antibody, Non-Fucosylated (CAT#: BioBet-342ZP) Datasheet

LOXL2

Simtuzumab; 1318075-13-6; AB0024; GS-6624; LOXL2; lysyl oxidase-like 2; lysyl oxidase homolog 2; WS9 14; lysyl oxidase related 2; lysyl oxidase-like protein 2; lysyl oxidase-related protein 2; lysyl oxidase-related protein WS9-14; LOR2; WS9-14;

Extracellular region or secreted, Nucleus, Endoplasmic reticulum

Diseases associated with LOXL2 include Hyperostosis Cranialis Interna and Mid-Dermal Elastolysis.

Its related pathways are Degradation of the extracellular matrix and Collagen chain trimerization.

Mediates the post-translational oxidative deamination of lysine residues on the target protein, leading to the formation of allysine. As a transcriptional co-repressor, it specifically mediates the trimethylated'Lys-4' deamination of histone H3 (H3K4me3), which is a specific marker of apparent transcriptional activation. Loxl2-mediated deamination of TAF10 leads to transcriptional repression of genes required for embryonic stem cell pluripotency including POU5F1/OCT4, NANOG, KLF4 and SOX2 (similar). It participates in epithelial cell to mesenchymal transition (EMT) through its interaction with SNAI1, and participates in the inhibition of E-cadherin CDH1, possibly by mediating the deamination of histone H3. It interacts with the endoplasmic reticulum protein HSPA5 and activates the IRE1-XBP1 pathway of unfolded protein response, leading to the expression of several transcription factors involved in EMT and subsequent EMT induction. Participation in E-cadherin inhibition after hypoxia, which is a feature of EMT, is believed to enhance tumor aggressiveness, suggesting that it may play a role in tumor progression. When secreted into the extracellular matrix, it mediates the oxidative deamination of peptide lysine residues in the precursor to generate fibrous collagen and elastin, which promotes the cross-linking of extracellular matrix proteins. As a regulator of angiogenesis, type IV collagen scaffolds may be used. As a regulator of chondrocyte differentiation, it is possible to regulate the expression of factors that control chondrocyte differentiation (through similarity).

The lysine tyrosylquinone cross-link (LTQ) is generated by condensation of the epsilon-amino group of a lysine with a topaquinone produced by oxidation of tyrosine. N-glycosylated. N-glycosylation on Asn-455 and Asn-644 may be essential for proper folding and secretion; may be composed of a fucosylated carbohydrates attached to a trimannose N-linked glycan core.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG4, κ

BioBet-342ZP

Humanized

Human

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human LOXL2. Simtuzumab is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator.

Myelofibrosis

Myelofibrosis